EAM Investors’s Atara Biotherapeutics ATRA Stock Holding History

EAM Investors’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,987	Closed	-$975K	–	339
2020 Q4	$975K	Buy	+1,987	New	+$917K	0.16%	270
2015 Q3	–	Sell	-717	Closed	-$946K	–	294
2015 Q2	$946K	Buy	+717	New	+$823K	0.11%	297

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

EAM Investors's ATRA Position: Q1 2021 in Review

EAM Investors sold out of Atara Biotherapeutics (ATRA) in Q1 2021, closing a stake of 1,987 shares — an estimated $975K sold.

EAM Investors first reported a position in ATRA in Q2 2015 and held it in 2 quarters. The position peaked at $975K in Q4 2020. 151 funds tracked by Wall St. Rank hold ATRA as of Q1 2021.

EAM Investors reported no remaining Atara Biotherapeutics position as of Q1 2021 after selling out during the quarter.
EAM Investors sold 1,987 Atara Biotherapeutics shares in Q1 2021, an estimated $975K.
EAM Investors first reported a position in Atara Biotherapeutics in Q2 2015 and held it in 2 quarters.
EAM Investors's Atara Biotherapeutics position peaked at $975K in Q4 2020.
151 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2021.

Based on EAM Investors's 13F filing for Q1 2021, filed 11 May 2021.